Study Confirms Febuxostat Utility in Reducing Serum Uric Acid to Goal Among ... - DG News

Study Confirms Febuxostat Utility in Reducing Serum Uric Acid to Goal Among ... DG News ... with mild to moderate renal impairment. [Presentation title: Febuxostat for the Treatment of Chronic Recurrent Gout: A Meta-Analysis. Abstract SAT0374] EULAR: Meta-Analysis Confirms Febuxostat Utility in Gout PatientsMedPage Today all 2 news articles »

Investigative Canakinumab Eases Pain Better Than Steroid Therapy in Patients ... - DG News

Investigative Canakinumab Eases Pain Better Than Steroid Therapy in Patients ... DG News ROME -- June 21, 2010 -- Patients with gout who were treated with a high dose of the investigative anti-inflammatory biologic canakinumab ... Study shows Novartis' ACZ885 prevents acute flares in gout patientspharmabiz.com all 3 news articles »

Nuon Therapeutics Announces Results of Studies Confirming the Uric Acid ... - MarketWatch (press release)

Nuon Therapeutics Announces Results of Studies Confirming the Uric Acid ... MarketWatch (press release) "These findings suggest that tranilast could be an important addition for the treatment of patients with chronic gout," said Michael Kitt, MD, ... and more »

Ardea touts good gout drug candidate study results - BusinessWeek

Ardea touts good gout drug candidate study results BusinessWeek Both hyperuricemia and gout lead to symptoms including swelling and pain in joints. An early stage study of RDEA594 showed a 100 percent response rate when ... CORRECT: Ardea Announces Additional Positive Results On Gout DrugWall Street Journal Positive Phase 2 Data on RDEA594, Ardea Biosciences' Lead Product Candidate ...PR Newswire (press release) Positive Phase 2 Data on RDEA594, Ardea Biosciences' Lead Product Candidate ...MarketWatch (press release) Daily Markets all 34 news articles »